תחזית צמיחת רווח נקי למניה לשנה הבאה Innate Pharma (IPHA)

Innate Pharma S.A. (IPHA) revenues are based on grants and licenses, foreshadowing future sales growth in immunotherapy. On GURU.Markets, the trend in expected earnings per share reflects current trajectories, where the -232.10 metric determines the parameter status. Partnerships with tech giants ensure R&D stability, while outsourcing antibody production in France minimizes the company's operational risks.

This indicator measures the market's weighted average expectation for net earnings per share dynamics by aggregating daily analyst estimate revisions. For Innate Pharma S.A. (IPHA), this vector determines whether royalty payments from partners can offset oncology research costs. By analyzing the consensus for next year's earnings per share changes, an investor can identify shifts in the expected return. The resulting trajectory establishes a long-term benchmark for fundamental value.